Alnylam Pharmaceuticals, Inc. Financials

Market Capitalization $43.00 Billion as of July 1, 2025

Valuations Metrics as of Jul. 4, 2025

Trailing PE
Forward PE	-270.30
Price to Sales TTM	$18.31
Price to Book MRQ	$372.20
Enterprise to Revenue	18.15
Enterprise to EBITDA	-736.98

Financial Reports as of Mar. 31, 2025

Financials

Fiscal Year Ends	2024-12-31
Most Recent Quarter	2025-03-31
Profit Margin	-11.49%
Operating Margin	3.04%
Return on Assets TTM	-1.79%
Return on Equity TTM	-414.62%

Income Statement

Revenue TTM	$2,348,099,072
Revenue per Share TTM	$18.27
Quarterly Revenue Growth	20.20%
Gross Profit TTM	$2,019,664,000
EBITDA	$-57,815,000
Net Income to Common TTM	$-269,700,992
Diluted EPS TTM	$-2.11
Quarterly Earnings Growth YoY	20.20%

Balance Sheet

Total Cash MRQ	$2,632,221,952
Total Cash per Share MRQ	$20.19
Total Debt MRQ	$
Total Debt to Equity MRQ	2358.26
Current Ratio MRQ	3.04
Book Value per Share MRQ	$0.89

Cash Flow

Operating Cash Flow TTM	$-45,111,000
Levered Free Cash Flow TTM	$223,088,000

ALNY Stock Info as of Jul. 4, 2025

Stock Statistics

Shares Outstanding	129,294,000
Float Shares	125,463,623
Avg 10 Volume	1,032,110
Avg 30 Volume	None
Shares Short	3,375,720
Short Ratio	3.72
Short % of Shares	3.42%
% Held by Insiders	3.80%
% Held by Institutions	97.50%

Stock Price Summary

Beta	0.21
Fifty Two Week Low	$205.87
Fifty Two Week High	$333.70
Fifty Two Week Change	24.37%
Day 50 MA	$289.08
Day 200 MA	$266.66

Dividends and Splits

Forward Annual Dividend Rate	$
Forward Annual Dividend Yield	%
Trailing Annual Dividend Rate	$0.00
Trailing Annual Dividend Yield	0.00%
Payout Ratio	0.00%
Dividend Date
Ex Dividend Date
Last Split Factor
Last Split Date